

OD22 Innovating Patient Involvement In Health Technology Assessments To Enable More Sustainable Involvement From Patient Stakeholders

Heidi Livingstone, Ella Fitzpatrick, Mandy Tonkinson, Helen Crosbie, Mark Rasburn

(Mark.Rasburn@nice.org.uk), Sally Taylor and Janine Wigmore

Introduction: The National Institute for Health and Care Excellence (NICE) heard from small organizations how resource intensive and difficult it is for them to participate in medicines health technology assessments (HTA) since the COVID-19 pandemic. To provide additional support for these organizations or to provide alternative patient input, NICE explored implementing surveys directly with patients to share with patient stakeholder organizations and NICE's HTA medicines committees.

Methods: Patient organizations and colleagues at NICE were included in the background investigation. Informal interviews were conducted with the HTA bodies in Wales and health technology colleagues in NICE about their experience of this method of patient input.

Two approaches were piloted:

- (i) Developing the online questionnaire using the Summary of Information for Patients.
- (ii) Developing a jointly branded questionnaire collaboratively with the patient organization and implementing a data-sharing agreement to share the raw data.

The survey was distributed by the patient organization, analyzed by NICE, and shared with the patient organization to inform their submission to NICE.

Results: The results of the background investigation showed that the option to include this additional method of input could provide valuable support for patient organizations and has the potential to increase the amount and quality of patient input to an HTA committee.

Both pilots were successful in:

- Supporting patient organizations' input into a medicines HTA
- Reducing the resources required from patient organizations.

The second pilot added more value due to:

- Collaboration, relationship, and building trust
- Joint development of the survey
- Data sharing and potential to add to patient evidence about a disease and treatments.

Conclusions: Surveys conducted directly with patients can help patient organizations participate in medicines HTAs, but they are only one element of developing more innovative and sustainable patient involvement in the process. HTA bodies need to innovate

and work collaboratively with patient stakeholders to produce a menu of options for involvement so that it can be tailored to stakeholders' resources.

OD23 Evolving Prostate Cancer Screening Strategies In Germany: A Cost–Utility Analysis Comparing Traditional And Emerging Modalities

Muchandifunga T. Muchadeyi, Shuang Hao, Karla Hernandez-Villafuerte, Shah Khan, Nikolaus Becker, Agne Krilaviciute, Petra Seibold, Roman Gulati, Peter Albers, Michael Schlander

(m.schlander@dkfz-heidelberg.de) and Mark Clements

Introduction: In 2021, approximately 15,000 men in Germany died from prostate cancer (PCa). The national health policy is considering shifting from annual digital rectal examination (DRE)-based screening to an age-related prostate-specific antigen (PSA)-based risk-adapted and organized screening strategy. Our research investigated the cost–utility of the current DRE-based strategy versus organized age-related PSA-based risk-adaptive PCa screening strategies in Germany.

Methods: We adapted the Swedish Prostata model to the German context, recalibrating it with PCa clinical and epidemiological data from the national and state registries. The model includes preclinical and clinical disease health states defined by tumor, nodal, and metastatic stages and Gleason scores, and assumes that the benefits of screening arise from stage shift. We assessed the cost–utility of 14 strategies, ranging from no screening to DRE, and age-related, PSA-based, risk-adapted screening. Health state utility values and test characteristics were sourced from the literature. Inpatient and outpatient care costs were derived from the German diagnostic-related groups and uniform-based valuation systems.

Results: Among all strategies evaluated and compared with no screening, the “DRE only” strategy led to substantial overdiagnosis, the highest incremental cost, and minimal quality-adjusted life years (QALY) gains. PSA testing starting at 50 to 60 years with reflex MRI for PSA greater than 3 ng/mL cases followed by combined systemic and targeted biopsy reduced the number of biopsies and overdiagnosis by 75 percent and 26 percent, albeit for fewer QALYs and higher costs (dominated) than the same strategy without reflex MRI. The PSA-based risk-adaptive strategy, starting at 50 to 60 years without reflex MRI, demonstrated an 85 percent probability of being cost effective within the EUR30,000 (USD32,211) to EUR100,000 (USD107,369)/QALY willingness-to-pay range.

Conclusions: While Germany's HTA emphasizes clinically added benefits and health-related quality of life, cost-effectiveness analysis substantiates this evidence. As a standalone early detection tool, DRE leads to substantial overdiagnosis, unnecessary biopsies, and